Earnings

Which is more compelling pick right now? – Bristol-Myers Squibb Company (BMY), HCP, Inc. (HCP)

The shares of Bristol-Myers Squibb Company have decreased by more than -14.80% this year alone. The shares recently went down by -0.17% or -$0.09 and now trades at $52.21. The shares of HCP, Inc. (NYSE:HCP), has slumped by -10.54% year to date as of 05/16/2018. The shares currently trade at $23.33 and have been able to report a change of -2.30% over the past one week.

The stock of Bristol-Myers Squibb Company and HCP, Inc. were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Next 5Y EPS Growth: 10.99% versus 2.50%

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that BMY will grow it’s earning at a 10.99% annual rate in the next 5 years. This is in contrast to HCP which will have a positive growth at a 2.50% annual rate. This means that the higher growth rate of BMY implies a greater potential for capital appreciation over the years.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. BMY has an EBITDA margin of 27.06%, this implies that the underlying business of HCP is more profitable. The ROI of BMY is 20.20% while that of HCP is 2.60%. These figures suggest that BMY ventures generate a higher ROI than that of HCP.

Cash Flow



The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, BMY’s free cash flow per share is a positive 1.34, while that of HCP is positive 0.51.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The debt ratio of BMY is 0.60 compared to 1.53 for HCP. HCP can be able to settle its long-term debts and thus is a lower financial risk than BMY.

Valuation

BMY currently trades at a forward P/E of 14.15, a P/B of 6.67, and a P/S of 4.05 while HCP trades at a forward P/E of 36.57, a P/B of 2.10, and a P/S of 5.97. This means that looking at the earnings, book values and sales basis, BMY is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions




The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of BMY is currently at a -11.81% to its one-year price target of 59.20. Looking at its rival pricing, HCP is at a -7.82% relative to its price target of 25.31.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), BMY is given a 2.50 while 2.70 placed for HCP. This means that analysts are more bullish on the outlook for HCP stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for BMY is 1.46 while that of HCP is just 2.89. This means that analysts are more bullish on the forecast for BMY stock.

Conclusion

The stock of HCP, Inc. defeats that of Bristol-Myers Squibb Company when the two are compared, with HCP taking 3 out of the total factors that were been considered. HCP happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, HCP is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for HCP is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Olin Corporation (OLN) and H.B. Fuller Company (FU... Olin Corporation (NYSE:OLN) shares are up more than 41.51% this year and recently increased 0.03% or $0.01 to settle at $36.24. H.B. Fuller Company (N...
Albemarle Corporation (ALB) and PPG Industries, In... Albemarle Corporation (NYSE:ALB) and PPG Industries, Inc. (NYSE:PPG) are the two most active stocks in the Specialty Chemicals industry based on today...
Choosing Between Microsoft Corporation (MSFT) and ... Microsoft Corporation (NASDAQ:MSFT) shares are up more than 24.96% this year and recently increased 0.21% or $0.16 to settle at $77.65. Cognizant Tech...
Comparing Valuation And Performance: Kimco Realty ... The shares of Kimco Realty Corporation have decreased by more than -23.14% this year alone. The shares recently went down by -0.29% or -$0.04 and now ...
Should You Buy Cyclacel Pharmaceuticals, Inc. (CYC... Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) shares are down more than -67.30% this year and recently increased 3.84% or $0.07 to settle at $1.80. Por...